2 Feb 2022 , 09:39 AM
In its press release on Wednesday, Alembic Pharmaceuticals Limited announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fesoterodine Fumarate ExtendedRelease Tablets, 4 mg, and 8 mg.
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Toviaz Extended-Release Tablets, 4 mg, and 8 mg, of Pfizer Inc. (Pfizer). Fesoterodine Fumarate ExtendedRelease Tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses.
Fesoterodine Fumarate Extended-Release Tablets, 4 mg, and 8 mg have an estimated market·size of US$ 225 million for twelve months ending September 2021 according to IQVIA.
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company, engaged in the healthcare sector since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products around the world.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.